Venetoclax treatment options

Venetoclax (Venetoclax), as an oral BCL-2 inhibitor, is widely used in chronic lymphocytic leukemia (CLL< /span>), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). Treatment plans are often customized based on the patient's specific disease type, disease stage, and personal health status. Below are common treatment options and details for venetoclax.

For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), venetoclax is often given in combination with obinutuzumab (Obinutuzumab) or rituximab (Rituximab). Treatment is initiated with venetoclax in a stepwise dose escalation approach to reduce the risk of tumor lysis syndrome (TLS). Patients typically start at a low dose of 20 mg per day during the first week and then gradually increase to the standard dose of 400 mg over the following weeks. This step-up process helps ensure patient tolerance of the drug and avoids acute adverse reactions.

For patients with acute myeloid leukemia (AML), especially older patients who are not candidates for intensive chemotherapy or those with comorbidities, venetoclax is often combined with a low-dose chemotherapy drug such as azacitidine (Azacitidine ), decitabine (Decitabine) or low-dose cytarabine (Cytarabine). In these combination regimens, the dose of venetoclax is usually around 600 mg and may be adjusted based on the patient's health and response. During treatment, doctors will closely monitor the patient's blood indicators to ensure the safety and effectiveness of the drug.

For some patients with CLLLonger-term treatment may lead to longer-lasting relief, especially in combination regimens. Studies have shown that the combination of venetoclax and obinutuzumab significantly prolonged the progression-free survival of patients after a 12-month course of treatment. However, the duration of treatment will vary based on individual treatment response and side effects, and sometimes doctors may continue to observe and evaluate the need for maintenance treatment after 12 months.